Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Study links high serum enzyme to liver cancer:

This article was originally published in Clinica

Executive Summary

Measuring the level of an enzyme in serum could help doctors identify which patients with hepatitis C virus-associated cirrhosis are at risk of rapidly developing liver cancer, according to a Japanese team. A seven-year follow-up study, published in Cancer (August 15), showed that the five-year incidence rate of hepatocellular carcinoma was 53.6% in patients with persistently high levels of the enzyme alanine aminotransferase (ALT) compared with 7.1% in those with persistently low levels of the enzyme. The team suggested that patients with high serum ALT levels may benefit from intensive surveillance using medical imaging.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079252

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel